This ADC product is comprised of an anti-SLC39A6 monoclonal antibody conjugated via a VC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAE binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
ADC Target
- Alternative Names
- SLC39A6; solute carrier family 39 (zinc transporter), member 6; LIV-1; zinc transporter ZIP6; ZIP-6; zrt-and Irt-like protein 6; estrogen-regulated protein LIV-1; LIV-1 protein, estrogen regulated; solute carrier family 39 member 6; solute carrier family
- Target Entrez Gene ID
- 25800
- Overview
- Zinc is an essential cofactor for hundreds of enzymes. It is involved in protein, nucleic acid, carbohydrate, and lipid metabolism, as well as in the control of gene transcription, growth, development, and differentiation. SLC39A6 belongs to a subfamily of proteins that show structural characteristics of zinc transporters (Taylor and Nicholson, 2003 [PubMed 12659941]).
ADC Antibody
- Overview
- Humanized Anti-SLC39A6 lgG1 Antibody, huB4
ADC Linker
- Name
- VC (valine-citrulline)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
- Name
- MMAE (Monomethyl auristatin E)
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products